Gunda, Viswanath
Gigliotti, Benjamin
Ndishabandi, Dorothy
Ashry, Tameem
McCarthy, Michael
Zhou, Zhiheng
Amin, Salma
Freeman, Gordon J.
Alessandrini, Alessandro
Parangi, Sareh http://orcid.org/0000-0003-1280-2812
Funding for this research was provided by:
Harvard Medical School (Eleanor and Miles Schore Fellowship)
American Thyroid Association (ThyCa Grant)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK00702842)
Scholarship from the Department of Pathology, College of Medicine, Kind Saud University
U.S. Department of Health & Human Services | National Institutes of Health (P01AI123086, P01AI056299)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA101942, 1R01CA149738)
Article History
Received: 14 March 2018
Revised: 17 August 2018
Accepted: 19 September 2018
First Online: 17 October 2018
Competing interests
: Dr. G.J.F. has patents/pending royalties on the PD-1 pathway from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Dako and Novartis. Dr. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, and Quiet. All the remaining authors declare no competing interests.
: All animal experiments were conducted at the Massachusetts General Hospital with oversight from the Massachusetts General Hospital Institutional Animal Care and Use Committee, and in accordance with federal, local, and institutional guidelines.
: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0)